Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
- Nizar J. Bahlis
- , Meletios A. Dimopoulos
- , Darrell J. White
- , Lotfi Benboubker
- , Gordon Cook
- , Merav Leiba
- , P. Joy Ho
- , Kihyun Kim
- , Naoki Takezako
- , Philippe Moreau
- , Jonathan L. Kaufman
- , Maria Krevvata
- , Christopher Chiu
- , Xiang Qin
- , Linda Okonkwo
- , Sonali Trivedi
- , Jon Ukropec
- , Ming Qi
- , Jesus San-Miguel
- University of Calgary
- National and Kapodistrian University of Athens
- QEII Health Sciences Centre
- Centre Hospitalier Régional Universitaire de Tours
- Leeds Teaching Hospitals NHS Trust
- Assuta Ashdod Hospital
- Royal Prince Alfred Hospital
- National Hospital Organization Disaster Medical Center
- University Hospital Hôtel-Dieu
- Emory University
- Johnson & Johnson
- Janssen Global Medical Affairs
- University of Navarra
Research output: Contribution to journal › Article › peer-review
213
Link opens in a new tab
Scopus
citations